Management of a human immunodeficiency virus case with discordant antiviral drug resistance profiles in cerebrospinal fluid compared with plasma: a case report.
PMID: 35164871
2022
Journal of medical case reports
Conclusion: During subsequent years, the plasma resistance pattern reverted to susceptible for the NRTI/NNRTIs; however the PI mutation L89V appeared, only later to revert to fully susceptible again.
Conclusion: The PI L89V mutation may contribute to reduced PI susceptibility.
Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients.
Introduction: Following the Stanford algorithm (mutation list), minor resistance mutations (L10F, V11I, K20TV, L23I, L33F, K43T, F53L, Q58E, A71IL, G73STCA, T74P, N83D, and L89V) are assumed to have ancillary roles such as compensation for lower efficiency of proteolysis caused by major mutations; major resistance mutations (V32I, M46IL, I47VA, G48VM, PMID: 35061671
2022
PloS one
Table: L89V
Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.
Abstract: Three candidate PI-SDRMs were accessory darunavir-resistance mutations (L10F, T74P, L89V).
Result: T74P and L89V were considered to be accessory mutations based on analyses of phenotypic and clinical data derived from the POWER studies that led the FDA approval of darunavir.
Result: Figure 3 shows the locations of the PI-SDRMs and the three candidate mutations (L10F, T74P, and L89V) within the three-dimensional structure of HIV-1 protease.
Result: Three of the mutations were on four expert lists including L10F, T74P, a
Genotyping and antiretroviral drug resistance of human immunodeficiency Virus-1 in Jazan, Saudi Arabia.
Abstract: Mutations associated with antiretroviral drugs include (V82A+I84IV), (L10F+Q58E), (L10F+V82Y), L10FV, L33LF, L89LMV, M184V, E138A, V106I, and V179VD.
Result: Among the observed resistance mutations, 4/57 (7.0%) had conferring resistance to PI, other detected mutations were (L10F + V82Y), L10FV, L33LF, and PMID: 32119691
2020
PloS one
Table: L89V
Molecular Determinants of Epistasis in HIV-1 Protease: Elucidating the Interdependence of L89V and L90M Mutations in Resistance.
Introduction: The L89V mutation in HIV-1 protease is a so-called accessory mutation that is present in patient-derived isolates and is associated with resistance to DRV inhibition.
Result: From examining the computed JSD between KY and KY(V89L) for the all dihedral angles, the effects of the L89V mutation are clearly visible throughout the protease, including the alpha-helix, 70's loop and flap elbows (Figure 6D).
Result: The L89V mutation, located in the alpha-helix, induces structural changes at residue I71 (Figure 6D).
Result: The catalytic efficiency of the NL4-3(L89V) variant was reduced 57fold, relative to WT, with KM increasing 1.5-fold and kcat decreasing by 96-fold.
Result: The presence of the Protease: Elucidating the Interdependence of L89V and L90M Mutations in Resistance.
1Abstract: The focus of our investigation is a patient-derived isolate, with 24 mutations that we call ""KY""; this variant includes the L89V and L90M mutations."
Abstract: In this study, we investigated the interdependence between the L89V and L90M mutations and their effects on DRV binding.
Abstract: When a leucine to valine mutation at residue 89 is present simultaneously with the L90M mutation, a rescue of catalytic efficiency is observed.
Introduction: As DRV binds wild-type (WT) sequences of HIV-1 protease with high affinity (<5pM), binding assays are generally not adequately sensitive to detect the relative impact of the L89V and L90M single amino acid substitu
Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.
Discussion: reported that 11 amino acid substitutions, V11I, V32I, L33F, I47V, I50V, I54L/M, G73S, L76V, I84V, and L89V, which appear to be associated with HIV-1 resistance against DRV, were identified among HIV-1 variants isolated from patients treated with DRV-including regimens on POWER studies.
Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy.
Abstract: NGS revealed previously unidentified minority variant protease mutations (G73D, I54T, L89V) in three samples, at frequencies ranging between 2% and 10%.
Result: The L89V mutation (frequency 5%), which predicts resistance to fosamprenavir, was detected at 41 weeks in patient C.
HIV mutation literature information.
PMID: 
2022
Journal of medical case reports
Browser Board
Co-occurred Entities
Filtrator
ViMRT